share_log

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

每日生物科技脉搏:分子合作伙伴因双重坏消息而暴跌,辉瑞/生物科技寻求新冠肺炎入股儿童,辉瑞投资Zentaris
Benzinga Real-time News ·  2022/04/27 08:46
Here's a roundup of top developments in the biotech space over the last 24 hours.
以下是过去24小时生物技术领域的最新进展综述。
Stocks In Focus
关注的股票
Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years
辉瑞和BioNTech寻求紧急使用5-11岁儿童新冠肺炎疫苗
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age.
辉瑞(纽约证券交易所股票代码:PFE)和BioNTech SE纳斯达克(美国新浪纳斯达克股票代码:BNTX)已经提交了美国食品和药物管理局紧急使用授权(EUA)申请,为5至11岁的儿童提供10微克加强剂量的新冠肺炎疫苗。
The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately six months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-µg two-dose primary series.
提交的材料包括2/3期临床试验的数据,试验对象为5至11岁的儿童,他们在辉瑞-生物科技新冠肺炎疫苗10微克两剂初级系列疫苗第二剂接种约六个月后接受了加强剂量。
Molecular...
分...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发